AmbioPharm, a company involved in peptide active pharmaceutical ingredient (API) contract development and manufacturing organization (CDMO) services, appointed industry veteran Brian Gregg CEO. Gregg, who has more than 30 years of experience in the peptide CDMO industry, succeeds Tim Nieters, who will be stepping down after seven years with the company.

Gregg joins AmbioPharm following a 32-year career at Bachem Americas, where he was COO for nearly a decade and was responsible for driving business and operational growth with the strategic acquisition and integration of a competing peptide CDMO. During his earlier years at Bachem, Gregg led the quality and regulatory function for Bachem Americas before serving as site manager for Bachem’s GMP manufacturing location in Torrance, CA.

Gregg will play a pivotal role in expanding AmbioPharm’s leadership role in the growing peptide CDMO market and growing the company’s global customer base.

Juncai Bai, chairman of the company, said, “We are excited to welcome Brian to our executive team. He has both the leadership experience and necessary background to be immediately effective in growing our business in the U.S. and globally, and we look forward to working with him as we continue to expand on our service offerings and global customer base.”

Gregg said, “AmbioPharm has invested significant effort and capital building out its systems, organization, buildings, and equipment, and the company is well-positioned to capture the opportunities in the global peptide CDMO market. It is an exciting time to take the reins of the company and I look forward to working with the leadership team to capitalize on these opportunities as well as to deliver high-quality products and service excellence for AmbioPharm’s customers.”